pridopidine
Small moleculeexperimental
Pridopidine is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). — Wikipedia
Clinical trial activity
10 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00665223)
Timeline
Indications
Mechanism of action
- Dopamine D2 receptorMODULATOR
DRD2 modulator
Dopaminergic stabilizer
Chemistry & pharmacology
Loading structure…
SMILES
CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1- Mol. weight
- 281.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPridopidine ↗
- ChEMBLCHEMBL596802 ↗
Also known as
- 4-(3-methanesulfonylphenyl)-1-propylpiperidine
- 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine
- acr16
- acr16
- acr16
- acr16 compound
- fr-310826
- fr-310826
- huntexil
- pridopidine
- pridopidine
- pridopidine
- pridopidine
- pridopidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04615923 | Phase 2/Phase 3 (Phase 3) | Dec 18, 2020 | Harvard University, Prilenia |
| NCT04556656 | Phase 3 | Oct 16, 2020 | Prilenia |
| NCT03922711 | Phase 2 | Mar 26, 2019 | Prilenia |
| NCT03019289 | Phase 1 | Mar 20, 2017 | Teva |
| NCT02494778 | Phase 2 | Sep 30, 2015 | Teva |
| NCT02006472 | Phase 2 | Feb 1, 2014 | European Huntington's Disease Network, Huntington Study Group, Teva |
| NCT01306929 | Phase 2 | Mar 1, 2011 | Teva, University of Rochester |
| NCT00724048 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2008 | NeuroSearch A/S, Teva |
| NCT00665223 | Phase 3 | Apr 1, 2008 | Teva |
| NCT06069934 | N/A | — | Harvard University, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Prilenia |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 6 | 6 | 3 | 2008 |
| Prilenia | For profit | 4 | 3 | 3 | 2019 |
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| European Huntington's Disease Network | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Huntington Study Group | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | — |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | — |
| NeuroSearch A/S | For profit | 1 | 0 | 1 | 2008 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2011 |
9 organizations
Page 1 / 1